加载中
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
前收盘价
US$10.31
−US$0.52 · -4.80%
盘前
US$10.20
−US$0.11 · -1.07%
10月14日 9:08 ET
盘中时间采用ET。市场数据可能有所延迟。
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
日内区间
当前US$10.31
52周区间
当前US$10.31
盘中时间采用ET。市场数据可能有所延迟。
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
日内区间
当前US$10.31
52周区间
当前US$10.31
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 9.7万 USD | — | — | — | — |
| 毛利 | −9.7万 USD | — | — | — | — |
| 研究与开发 | 4661.6万 USD | 1433.6万 USD | 1541.1万 USD | 2621.4万 USD | 2332.2万 USD |
| 销售、一般及管理费用 | 2117万 USD | 1602.5万 USD | 2486.4万 USD | 1892.1万 USD | 1235万 USD |
| 营业费用 | 6778.6万 USD | 8202万 USD | 4027.5万 USD | 4513.5万 USD | 3567.2万 USD |
| 利息收入 | 832.3万 USD | 813.2万 USD | 462万 USD | 137.5万 USD | — |
| 折旧和摊销 | 9.7万 USD | — | — | — | — |
| 营业利润 | −6788.3万 USD | −8202万 USD | −4027.5万 USD | −4513.5万 USD | −3567.2万 USD |
| 净利润 | −5985.1万 USD | −7389.7万 USD | −3511.9万 USD | −4524.4万 USD | −4748万 USD |
公司数据更新于 2026年10月14日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
